Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study with 3 dose levels of IMO-2125 in combination with standard weight based ribavirin (investigational treatment arm) or placebo in combination with ribavirin (RBV). Each cohort of 15 patients will be randomized 4:1 to receive the investigational treatment arm (12 patients) or placebo and RBV arm (3 patients).
Critère d'inclusion
- Hepatitis C, Treatment Naïve, Genotype 1 Patients